Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19 | Zendy

Harmony R. Reynolds | Zendy; Samrachana Adhikari | Zendy; Claudia Pulgarin | Zendy; Andrea B. Troxel | Zendy; Eduardo Iturrate | Zendy; Stephen B. Johnson | Zendy; Anaïs Hausvater | Zendy; Jonathan Newman | Zendy; Jeffrey S. Berger | Zendy; Sripal Bangalore | Zendy; Stuart D. Katz | Zendy; Glenn I. Fishman | Zendy; Dennis Kunichoff | Zendy; Yu Chen | Zendy; Gbenga Ogedegbe | Zendy; Judith S. Hochman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Renin–Angiotensin–Aldosterone System Inhibitors and Risk of Covid-19

Author(s) -

Harmony R. Reynolds,

Samrachana Adhikari,

Claudia Pulgarin,

Andrea B. Troxel,

Eduardo Iturrate,

Stephen B. Johnson,

Anaïs Hausvater,

Jonathan Newman,

Jeffrey S. Berger,

Sripal Bangalore,

Stuart D. Katz,

Glenn I. Fishman,

Dennis Kunichoff,

Yu Chen,

Gbenga Ogedegbe,

Judith S. Hochman

Publication year - 2020

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa2008975

Subject(s) - renin–angiotensin system , aldosterone , covid-19 , medicine , pharmacology , blood pressure , disease , infectious disease (medical specialty)

There is concern about the potential of an increased risk related to medications that act on the renin-angiotensin-aldosterone system in patients exposed to coronavirus disease 2019 (Covid-19), because the viral receptor is angiotensin-converting enzyme 2 (ACE2).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research